| Compound Information | SONAR Target prediction |
| Name: | AMIODARONE HYDROCHLORIDE |
| Unique Identifier: | SPE02300165 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 651.534 g/mol |
| X log p: | 15.354 (online calculus) |
| Lipinksi Failures | 2 |
| TPSA | 38.77 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 4 |
| Rotatable Bond Count: | 11 |
| Canonical Smiles: | Cl.CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1 |
| Source: | synthetic |
| Reference: | Adv Drug Res 16: 309 (1987) |
| Therapeutics: | adrenergic agonist, coronary vasodilator, Ca channel blocker |
| Generic_name: | Amiodarone |
| Chemical_iupac_name: | (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone |
| Drug_type: | Approved Drug |
| Pharmgkb_id: | PA448383 |
| Kegg_compound_id: | C06823 |
| Drugbank_id: | APRD00288 |
| H2o_solubility: | 50000 mg/L (chloride salt) |
| Logp: | 7.706 |
| Cas_registry_number: | 1951-25-3 |
| Drug_category: | Vasodilator Agents; Enzyme Inhibitors; Anti-Arrhythmia Agents; ATC:C01BD01 |
| Indication: | Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia. |
| Pharmacology: | Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects. |
| Mechanism_of_action: | The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor. |
| Organisms_affected: | Humans and other mammals |
| Found: 201 active | as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [201] |
| Species: | 4932 |
| Condition: | AAT2 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.0992±0.0181726 |
| Normalized OD Score: sc h | 0.1347±0.0241269 |
| Z-Score: | -45.9520±0.270592 |
| p-Value: | 0 |
| Z-Factor: | 0.836126 |
| Fitness Defect: | INF |
| Bioactivity Statement: | Active |
| ps |
| DBLink | Rows returned: 11 | 1 2 Next >> |
| 2156 | 2-[4-(2-butylbenzofuran-3-carbonyl)-2,6-diiodo-phenoxy]ethyl-diethyl-azanium |
| 2157 | (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]methanone |
| 29770 | 2-[4-(2-butylbenzofuran-3-carbonyl)-2,6-diiodo-phenoxy]ethyl-diethyl-azanium chloride |
| 104774 | (2-butylbenzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodo-phenyl]methanone |
| 178801 | (2-butylbenzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodo-phenyl]methanone hydrochloride |
| 441325 | (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]methanone hydrochloride |
| internal high similarity DBLink | Rows returned: 2 |
| LOPAC 00166 | 1.0000 |
| RJC 02270 | 1.0000 |
| active | Cluster 5540 | Additional Members: 5 | Rows returned: 2 |
| RJC 02270 | 0 |
| LOPAC 00166 | 0 |
Service provided by the
Mike Tyers Laboratory